PUMA BIOTECHNOLOGY, INC. (PBYI) Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Puma Biotechnology, Inc. NASDAQ:PBYI Healthcare · Biotechnology
Mkt Cap $538.91M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Puma Biotechnology will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026, following the release of its third quarter 2026 financial results.
The release is a scheduling notice only and contains no financial results or guidance. Dial-in numbers and a live webcast via the company's investor-relations site are provided, with a 90-day replay archive.
• 10d ago AI analysis › Press Release
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology granted an inducement RSU award covering 7,500 shares to one new non-executive employee, approved by the Compensation Committee on October 1, 2026.
The award was made under the 2017 Employment Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4), vesting over three years subject to continued service.
This is a routine equity compensation disclosure with no material financial or strategic implications for PBYI.
• 27d ago AI analysis › Press Release ⚠ 2
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology initiated ALISCA-Lung2, a Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel, enrolling approximately 50 patients with advanced small cell lung cancer who progressed on or after platinum-based chemotherapy and immunotherapy.
The trial's primary endpoint is safety and tolerability of the combination, with secondary endpoints including objective response rate, duration of response, disease control rate, progression-free survival and overall survival, along with biomarker analysis to identify responsive patient subsets.
The new study runs alongside ALISCA-Lung1, Puma's Phase II trial of alisertib monotherapy in extensive stage small cell lung cancer, as the company broadens development of the aurora kinase A inhibitor it licensed in 2022; NERLYNX (neratinib) remains its sole marketed product.
• 1mo ago AI analysis › Press Release
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
Puma Biotechnology announced that Chairman, CEO, President and Founder Alan H. Auerbach will provide a company overview at 3:30 p.m. ET on Monday, September 14, at the H.C. Wainwright 28th Annual Global Investment Conference in New York City.
The conference runs September 14-16, 2026 at the Lotte New York Palace Hotel; a live webcast and slides will be available on Puma's investor site, with the presentation archived for 30 days.
This is a routine conference-scheduling notice containing no new clinical, financial, or regulatory data -- background only covers the marketed asset NERLYNX and the Phase II ALISCA alisertib trials.
• 1mo ago AI analysis › Press Release
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology's Compensation Committee approved inducement restricted stock unit awards covering 33,550 shares of common stock to five new non-executive employees on September 1, 2026.
The awards were granted under the company's 2017 Employment Inducement Incentive Award Plan, vest over three years, and were made as employment inducements under Nasdaq Listing Rule 5635(c)(4).
This is a routine equity-compensation disclosure with no operational or financial news; the share count is immaterial to PBYI's dilution profile and warrants no action from investors.
• 1mo ago AI analysis › Press Release ● Major ⚠ 2
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Puma Biotechnology reported Q2 2026 total revenue of $56.5 million, up from $52.4 million in the prior year, with net income reaching $8.2 million or $0.16 per share.
Management raised full-year 2026 guidance, increasing net product revenue expectations to $205-209 million and total revenue to $224-231 million, citing increased demand for NERLYNX.
The company is now debt-free following the final payment on its 2021 Note Purchase Agreement in May, ending the quarter with $93.9 million in cash and equivalents.
• 2mo ago AI analysis › Press Release
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology granted inducement restricted stock unit awards covering 35,375 shares to five new non-executive employees on August 3, 2026.
The awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) under the company's 2017 Employment Inducement Incentive Award Plan.
Vesting occurs over a three-year period, with one-third of the shares vesting on the first anniversary and the remainder vesting in equal semi-annual installments.
• 2mo ago AI analysis › Press Release
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
Puma Biotechnology announced it will host a conference call on August 6, 2026, to discuss its second quarter 2026 financial results.
The call is scheduled for 4:30 p.m. ET and can be accessed via live webcast or by dialing the provided domestic and international numbers.
A replay of the call will be available on the company's website for 90 days following the event.
• 3mo ago AI analysis › Press Release
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology granted inducement restricted stock unit awards covering 31,625 shares of common stock to four new non-executive employees on July 1, 2026.
The awards were approved by the Compensation Committee under the company's 2017 Employment Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over a three-year period, with one-third vesting on the first anniversary and one-sixth vesting on each subsequent six-month anniversary, subject to continued service.
• 4mo ago AI analysis › Press Release
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology disclosed the grant of 7,000 restricted stock units to two new non-executive employees.
The awards were issued as inducements under Nasdaq Listing Rule 5635(c)(4) and vest over three years.
This is a routine compliance disclosure with minimal dilutive impact on the shareholder base.
• 4mo ago AI analysis › Press Release ● Major
Puma Biotechnology Reports First Quarter 2026 Financial Results
Puma Biotechnology raised its full-year 2026 revenue and net income guidance, citing increased demand for NERLYNX, which is expected to result in a second consecutive year of demand growth.
The company reported Q1 total revenue of $44.8 million and a net loss of $3.8 million, with R&D expenses increasing by $6.0 million year-over-year to support alisertib clinical trials.
Puma eliminated all outstanding debt by remitting the final payment on its 2021 Note Purchase Agreement, ending the quarter with $101.5 million in cash and marketable securities.
• 5mo ago AI analysis › Press Release
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology granted inducement restricted stock units covering 59,750 shares to six new non-executive employees.
The awards vest over three years, starting May 1, 2026, and were approved under Nasdaq Listing Rule 5635(c)(4) as an inducement material to the employees entering into employment.
This is a routine administrative disclosure regarding employee compensation and does not change the company's business outlook.
• 5mo ago AI analysis › Press Release ● Major
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
businesswire.com • 6mo ago 
